

A

- ❖ **Acs G, Dumoff KL, Solin LJ, et al:** Extensive Retraction Artifact Correlates With Lymphatic Invasion and Nodal Metastasis and Predicts Poor Outcome in Early Stage Breast Carcinoma. *Am J Surg Pathol.* 31(1):129-40; 2007.
- ❖ **Acs G, Lawton TJ, Rebbeck TR, et al:** Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. *Am J Clin Pathol.* 115: 85-98; 2001.
- ❖ **Acs G, Simpson JF, Bleiweiss IJ, et al:** Microglandular adenosis with transition into adenoid cystic carcinoma of the breast. *Am J Surg Pathol.* 27(8):1052-60; 2003.
- ❖ **Adsay NV, Merati K, Nassar H, et al:** Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs. Coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. *Am J Surg Pathol.* 27: 571-8; 2003.
- ❖ **Ah-See MW, Burcombe RJ, Daley FM, et al:** Evaluation of tumor microvessel density & pericyte coverage index following neoadjuvant chemotherapy in primary breast cancer. *Meeting: ASCO Annual Meeting; Abstract No: 655;* 2005
- ❖ **Albertini JJ, Lyman GH, Cox C, et al:** Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. *JAMA.* 276:1818–22; 1996.
- ❖ **Albina JE and Mastrofrancesco B:** Modulation of glucose metabolism in macrophages by products of nitric oxide synthase. *American Journal of Physiology.* 264: C1594-9; 1993.

- ❖ **Albina JE and Reichner JS:** Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis. *Cancer & Metastasis Reviews*. 17: 39-53; 1998.
- ❖ **Albina JE, Cui S, Mateo RB, Reichner JS:** Nitric oxide-mediated apoptosis in murine peritoneal macrophages. *J Immunol*. 150: 5080-5; 1993.
- ❖ **Albina JE, Mills CD, Caldwell MD:** Alteration in macrophage physiology associated with the metabolism of L-arginine through the oxidative L-arginine deiminase pathway. In *Moncada S, Higgs EA, eds. Nitric Oxide from L-arginine: A Bioregulatory System* 1990. Amsterdam, Elsevier Science Publishers B.V; 1990.
- ❖ **Allred DC, Clark GM, Elledge R, et al:** Accumulation of mutant p53 is associated with increased proliferation and poor clinical outcome in node negative breast cancer. *J Natl Cancer Inst*. 85:200–6; 1993.
- ❖ **Allred DC, Clark GM, Molina R, et al:** Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. *Hum Pathol*. 23:974–9; 1992.
- ❖ **Al-Sarireh and Eremin:** Tumor-associated macrophages (TAMS): disordered function, immune suppression and progressive tumor growth. *J. R. Coll. Surg. Edinb*. 45: 1-16; 2000.
- ❖ **Amatangelo MD, Bassi DE, Klein-Szanto AJP, and Cukierman E:** Stroma-Derived Three-Dimensional Matrices Are Necessary and Sufficient to Promote Desmoplastic Differentiation of Normal Fibroblasts. *Am J Pathol*. 167(2): 475–88; 2005.
- ❖ **American Cancer Society:** Cancer Facts & Figures 2004. Atlanta, GA; 2004.

- ❖ **American Cancer Society:** Cancer facts and Figures: *Atlanta, GA. pp. 9-11*; 2007.
- ❖ **Andea AA, Bouwman D, Wallis T, et al:** Correlation of tumor size with survival in multifocal breast carcinoma. *Mod Pathol. 16:21a*; 2003.
- ❖ **Andersen TI, Gaustad A, Ottestad L, et al:** Genetic alterations of the tumor suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas. *Genes Chromosomes Cancer.4:113–21*; 1992
- ❖ **Aoe T and Saito T:** Towards immuno-modulation through the molecular mechanism of lymphocyte activation. *Nippon Rinsho. 53: 2331-9*; 1995.
- ❖ **Aschengrau, et al.:** *Am. J. Ind. Med.*, vol. 34, pp. 6-14, 1998
- ❖ **Atoum MF and Al Hourani HM:** Lifestyle related risk factors for breast cancer in Jordanian females. *Saudi Med J. 25:1245-8*; 2004.
- ❖ **Auger MJ and Ross JA:** The biology of macrophage. In Lewis CE, McGee JO, eds. *The Macrophage. Oxford: Oxford University Press. 2-74*; 1992.
- ❖ **Axelsson K, Ljung BM, Moore DH, et al:** Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. *J Natl Cancer Inst. 87:997–1008*; 1995.

B

- ❖ **Bae YK, Kim DS, Choi HJ, et al:** The significance of nuclear size in nuclear grade of invasive ductal carcinoma of the breast. *Korean J Cytopathol. 10(1): 21-6*; 1999.
- ❖ **Balch CM, Riley LB, Bae YJ, et al:** Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. *Arch Surg. 125:200-5*;

1990.

❖ **Balmain A, Gray J, Ponder B:** The genetics and genomics of cancer. *Nat Genet.* 33(suppl):238–44; 2003.

❖ **Barbera-Guillem E, Nyhus JK, Wolford CC, et al:** Vascular endothelial growth factor secretion by tumor-infiltrating macrophage essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. *Cancer Res.* 62 923): 7042-9; 2002.

❖ **Barnes DM and Hanby AM:** Estrogen and progesterone receptors in breast cancer: past, present and future. *Histopathology.* 38: 271-4; 2001.

❖ **Bartley AN and Ross DW:** Validation of p53 Immunohistochemistry as a Prognostic Factor in Breast Cancer in Clinical Practice. *Arch Pathol Lab Med.* 126(4): 456–8; 2002.

❖ **Basu A, Rowan BG, Basu A, Rowan BG:** Genes related to estrogen action in reproduction and breast cancer. *Frontiers in Bioscience.*10:2346-72; 2005.

❖ **Baumhueter S, Singer MS, Henzel W, et al:** Binding of L-selectin to the vascular sialomucin CD34. *Science.* 262: 436-40; 1993.

❖ **Bedwani R, Abdel-Fattah M, El Shazly M, Bassili A, Zaki A, Seif HA, et al:** Profile of familial breast cancer in Alexandria, Egypt. *Anticancer Res.* 21:3011-4; 2001.

❖ **Beilmann M, et al:** Human primary co-culture angiogenesis assay reveals additive stimulation and different angiogenic properties of VEGF and HGF. *Cytokine* 26(4): 178-85; 2004.

❖ **Bell DW, Varley JM, Szydlo, TE, et al:** Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. *Science.*286:2528–31; 1999.

- ❖ **Ben-Hur H, Cohen O, Schneider D, et al:** The role of lymphocytes and macrophages in human breast tumorigenesis: an immunohistochemical and morphometric study. *Anticancer Res.* 22(2B):1231-8; 2002.
- ❖ **Beral V, Bull D, Doll R, Peto R, Reeves G, Collaborative Group on Hormonal Factors in Breast Cancer:** Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. *Lancet.* 363:1007-16; 2004.
- ❖ **Bergh J, Norberg T, Sjogren S, et al:** Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. *Nat Med.* 1:1029–34; 1995.
- ❖ **Bertin N, Clezardin P, Kubiak R, et al:** Thrombospondin-1 and -2 messenger RNA expression in normal, benign and neoplastic human breast tissue: correlation prognostic factors, tumor angiogenesis and fibroblastic desmoplasia. *Cancer Res* 57: 396; 1997.
- ❖ **Berx G, Cleton-Jansen AM, Strumane K, et al:** E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. *Oncogene.* 13:1919; 1996.
- ❖ **Bhargava R, Gerald WL, Li AR, et al:** EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. *Mod Pathol.* 18(8):1027-33; 2005.
- ❖ **Bienstock RJ, Darden T, Wiseman R, et al:** Molecular modeling of the amino-terminal zinc ring domain of BRCA1. *Cancer Res.* 56:2539–

45; 1996.

❖ **Bingle L, Brown NJ and Lewis CE:** The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. *J Pathol* 196: 254-65, 2002.

❖ **Bissell MJ and Radisky D:** Putting tumours in context. *Nat Rev Cancer*.1:46–54; 2001.

❖ **Blachere NE, Li Z, Chandawarkar RY, et al:** Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. *J Exp Med*. 186: 1315-22; 1997.

❖ **Blobe GC, Schiemann WP, Lodish HF:** Role of transforming growth factor beta in human disease. *N Engl J Med*. 342(18): 1350-8; 2000.

❖ **Bohlke K, Spiegelman D, Trichopoulos A, et al:** Vitamins A, C and E and the risk of breast cancer: results from a case-control study in Greece. *Br J Cancer* 79 (1): 23-9; 1999.

❖ **Bolat F, Kayaselcuk F, Nursal TZ, et al:** MVD, VEGF expression, and TAMs in breast tumors: Correlations with prognostic parameters. *J. Exp. Clin. Cancer Res*. 25:3; 2006.

❖ **Bonner FT and Stedman G:** The chemistry of nitric oxide and redox-related species. In *Feelish M, Stamler JS, eds. Methods in Nitric Oxide Research*. Chichester, 1996.

❖ **Bonta IL, Ben-Efraim S, Mozes T, Fieren MW:** Tumour necrosis factor in inflammation: relation to other mediators and to macrophage antitumor defense. *Pharmacological Research*. 24: 115-30; 1991.

❖ **Boyd NF, Byng JW, Jong RA, et al:** Quantitative classification of mammographic densities and breast cancer risk: results from the

- Canadian National Breast Screening Study. *J Natl Cancer Inst* 87 (9): 670-5; 1995.
- ❖ **Boyd NF, Lockwood GA, Martin LJ, et al:** Mammographic densities and risk of breast cancer among subjects with a family history of this disease. *J Natl Cancer Inst* 91 (16): 1404-8; 1999.
- ❖ **Breast Cancer Linkage Consortium:** Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. *Lancet*.349:1505–10; 1997
- ❖ **Breast In: American Joint Committee on Cancer: AJCC Cancer Staging Manual.** 6th ed. New York, NY: Springer, pp 171-80, 2002.
- ❖ **Brinton LA and Devesa SS:** Incidence, demographics and environmental factors in: Diseases of the breast. *Philadelphia*. Vol. (1): 159-67; 1996.
- ❖ **Brooks P, Silletti S, Schalscha T, et al:** Disruption of angiogenesis by BEX, a noncatalytic metalloproteinase fragment with integrin binding activity. *Cell*. 92: 391; 1998.
- ❖ **Brown J, Greaves MF, Molgaard HV:** The gene encoding the stem cell antigen CD34 is conserved in mouse and expressed in haemopoietic progenitor cell lines, brain, and embryonic fibroblasts. *Int Immunol*. 3: 175-84; 1991.
- ❖ **Brown RW, Allred DC, Clark GM, et al:** Prognostic value of Ki67 compared to S phase fraction in axillary node-negative breast cancer. *Clin Cancer Res*. 2:585–92; 1996.
- ❖ **Buchholz TA, Wu X, Hussain A, et al:** Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. *International Journal of Cancer*. 97 (5):557-61; 2002.

- ❖ **Burke W, Daly M, Garber J, et al:** Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. *JAMA*.277:997–1003; 1997.
- ❖ **Byrne C, Schairer C, Wolfe J, et al:** Mammographic features and breast cancer risk: effects with time, age, and menopause status. *J Natl Cancer Inst* 87 (21): 1622-9; 1995.

C

- ❖ **Cao Y, Paner GP, Kahn LB, Rajan PB:** Noninvasive carcinoma of the breast: angiogenesis and cell proliferation. *Arch Pathol Lab Med*; Aug; 128(8):893-6, 2004.
- ❖ **Carey LA, Perou CM, Dressler LG, et al:** Race and the poor prognosis basal breast tumor (BBT) phenotype in the population-based Carolina Breast Cancer Study (CBCS). *Meeting: ASCO Annual Meeting*; Abstract No: 9510; 2004.
- ❖ **Carmalt HL, Mann LJ, Kennedy CW:** Carcinoma of the male breast: a review and recommendations for management. *Aust N Z J Surg*. 68(10): 712-5; 1998.
- ❖ **Carmeliet P and Jain RK:** Angiogenesis in cancer and other diseases. *Nature* 407: 249-57; 2000.
- ❖ **Carmichael A, Sami AS, Dixon JM:** Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation. *Eur J Surg Oncol*.29:475-9; 2003.
- ❖ **Carroll JS, Swarbrick A, Musgrove EA, et al:** Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells:

implications for the antiproliferative effects of antiestrogens. *Cancer Res.* 62:3126–31; 2002.

❖ **Carter CL, Allen C, Henson DE:** Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. *Cancer* 63:181–7; 1989.

❖ **Carter MR, Lester S, Fletcher CDM:** Metaplastic (spindle cell/sarcomatoid) carcinoma of the breast: analysis of 32 cases with evidence of aggressive behavior. *Mod Pathol.* 16:24a; 2003.

❖ **Cattoretti G, Rilke F, Andreola S:** p53 expression in breast cancer. *Int J Cancer.* 41:178–83; 1988.

❖ **Catzavelos C, Bhattacharya N, Ung YC, et al:** Decreased levels of the cell-cycle inhibitor p27^{Kip1} protein: prognostic implications in primary breast cancer. *Nat Med.* 3:227–30; 1997.

❖ **Chan PC and Dao TL:** Effects of dietary fat on age-dependent sensitivity to mammary carcinogenesis. *Cancer Lett J.* 18: 245; 1983.

❖ **Chang-Claude J, Eby N, Kiechle M, et al:** Breastfeeding and breast cancer risk by age 50 among women in Germany. *Cancer Cause Control* 11: 687-95; 2000.

❖ **Chen CL, Weiss NS, Newcomb P, et al:** Hormone replacement therapy in relation to breast cancer. *JAMA* 287 (6): 734-41; 2002.

❖ **Chen JJW, Lin YC, Yao PL, et al:** Tumor-associated macrophages: The double-edged sword in cancer progression. *Journal of Clinical Oncology.* 23 (5): 953-64; 2005.

❖ **Chhieng DC, Tabbara SO, Marley EF, et al:** Microvessel density and vascular endothelial growth factor expression in infiltrating lobular mammary carcinoma. *The Breast Journal.* 9 (3): 200-7; 2003.

- ❖ **Chlebowski RT, Chen Z, Anderson GL, et al:** Ethnicity and breast cancer: factors influencing differences in incidence and outcome. *J Natl Cancer Inst.* 97:439-48; 2005.
- ❖ **Chlebowski RT, Hendrix SL, Langer RD, et al.:** Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. *JAMA* 289 (24): 3243-53; 2003.
- ❖ **Chrysogelos SA and Dickson RB:** EGF receptor expression, regulation, and function in breast cancer. *Breast Cancer Res Treat.* 29:29–40; 1994.
- ❖ **Cid MC, Schnaper HW, Kleinman HK:** Estrogens and the vascular endothelium. *Ann N Y Acad Sci.* 966:143–57; 2002.
- ❖ **Clark GM:** Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. *Diseases of the Breast, Philadelphia, Pa: Lippincott-Raven.* 461–85; 1996.
- ❖ **Clark GM:** Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?. *J Natl Cancer Inst.* 90:1320–1; 1998.
- ❖ **Clemons M and Goss P:** Estrogen and the risk of breast cancer. *N Engl J Med.* 344: 267; 2001.
- ❖ **Cohn M, Middleton L, Valero V, et al:** Gastrointestinal metastases of carcinoma of the breast. *Mod Pathol.* 16: 26; 2003.
- ❖ **Colditz GA, Rosner BA, Speizer FE:** Risk factors for breast cancer according to family history of breast cancer. For the Nurses' Health Study Research Group. *J Natl Cancer Inst* 88 (6): 365-71; 1996.
- ❖ **Collaborative Group on Hormonal Factors in Breast Cancer:** Breast

cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. *Lancet* 360 (9328): 187-95; 2002.

❖ **Condeelis J and Pollard JW:** Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis. *Cell*. 124 (2): 263-6; 2006.

❖ **Condeelis J and Segall JE:** Intravital imaging of cell movement in tumours. *Nat. Rev. Cancer* 3: 921–930; 2003.

❖ **Condeelis J, Singer RH and Segall JE:** The great escape: When cancer cells hijack the genes for chemotaxis and motility. *Annu. Rev. Cell Dev. Biol.* 21: 695–718; 2005.

❖ **Connor AJM, Pinder SE, Elston CW, et al:** Intratumoral heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB-1 antibody. *Breast*. 6:171–176; 1997.

❖ **Contesso G, Rouesse J and Mouriessse H:** Prognostic factors of breast cancer. *Breast cancer J.* p 147; 1988.

❖ **Conway EM, Collen D, Carmeliet P:** Molecular mechanisms of blood vessel growth. *Cardiovasc Res* 49:507-21, 2001.

❖ **Cook LS, White E, Schwartz SM, et al:** A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States) *Cancer Causes Control* 7 (3): 382-90; 1996.

❖ **Couch FJ, DeShano ML, Blackwood MA et al:** BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. *New Engl J Med*.336:1409–15; 1997.

❖ **Cui S, Reichner JS, Mateo RB, Albina JE:** Activated murine

macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. *Cancer Res.* 54: 2462-7; 1994.

❖ **Cummings MC, Walsh MD, Hohn BG, et al:** Occult axillary lymph node metastases in breast cancer do matter: results of 10-year survival analysis. *Am J Surj Pathol.* 26: 1286-95; 2002.

D

❖ **Dabiri S, Huntsman D, Makretsov N, et al:** The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. *Modern Pathology* 17, 690-5, 2004.

❖ **Dai Y and Grant S:** Cyclin-dependent kinase inhibitors. *Curr Opin Pharmacol.* 3:362–370; 2003.

❖ **Dales JP, Garcia S, Carpentier S, et al:** Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. *Hum Pathol.* 35(2):176-83; 2004.

❖ **Damiani S, Peters JL, Eusebi V:** Malignant neoplasms infiltrating (pseudoangiomatous) stromal hyperplasia of the breast: an unrecognized pathway of tumor spread. *Histopathology.* 41: 208-15; 2002.

❖ **Dawson PJ, Baekey PA, Clark RA:** Mechanisms of multifocal breast cancer. An immunocytochemical study. *Hum Pathol.* 26:965-9; 1995.

❖ **De Jong JS, van Diest PJ, van der Valk P and Baak JPA:** Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II. Correlation with proliferation and angiogenesis. *J Pathol.* 184: 53-7; 1998.

❖ **de Mascarel I, Bonichon F, Coindre JM, Trojani M:** Prognostic

significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. *Br J Cancer*. 66:523–7; 1992.

❖ **De Young NJ and Gill PG:** Monocyte antibody-dependent cellular cytotoxicity in cancer patients. *Cancer Immunology, Immunotherapy*. 18: 54-8; 1984.

❖ **Delia D, Lampugnani MG, Renati M, et al:** CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro. *Blood*. 81: 1001-8; 1993.

❖ **Demirag F, Ünsal E, Yilmaz A, et al:** Prognostic Significance of Vascular Endothelial Growth Factor, Tumor Necrosis, and Mitotic Activity Index in Malignant Pleural Mesothelioma. *Chest*. 128:3382-7; 2005.

❖ **Denis M:** Human monocytes/macrophages: NO or no NO? *J Leukoc Biol*. 55: 682-4; 1994.

❖ **Desai KV, Xiao N, Wang W, et al:** Initiating oncogenic event determines gene-expression patterns of human breast cancer models. *Proc Natl Acad Sci USA*. 99:6967–72; 2002.

❖ **de-Waal-Malefyt R, Abrams J, Bennett B, et al:** Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. *J Exp Med*. 174: 1209-20; 1991.

❖ **Diab SG, Clark GM, Osborne CK, et al:** Tumor characteristics and clinical outcome of tubular and mucinous breast carcinoma. *J Clin Oncol*. 17: 1442-8; 1999.

❖ **Diallo R, Schaefer KL, Bankfalvi A, et al:** Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry. *Hum*

Pathol. 34(12):1299-305.; 2003.

❖ **Dickson R and Lippman M:** Molecular basis of breast cancer. In: Mendelsohn J, Howley P, Israel M, Liotta L (eds) *The molecular basis of cancer*, Saunders Co., Philadelphia, 358-84; 1995.

❖ **Dirkx AEM, oude Egbrink MGA, Wagstaff J and Griffioen AW:** Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. *Journal of Leukocyte Biology.* 80:1183-96; 2006.

❖ **Distler JH, et al:** Angiogenic and angiostatic factors in the molecular control of angiogenesis. *Quarterly Journal of Nuclear Medicine* 47(3): 149-61; 2003.

❖ **Donato NJ and Perez M:** Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells. *Journal of Biological Chemistry.* 273: 5067-72; 1998.

❖ **Donegan WL and Redlich PN:** Breast cancer in men. *Surg Clin North Am.* 76(2): 343-63; 1996.

❖ **Downward J:** Targeting RAS signaling pathways in cancer therapy. *Nat Rev Cancer.* 3:11–22; 2003.

❖ **Dressler LG, Eudey L, Gray R, et al:** Prognostic potential of DNA flow cytometry measurement in node-negative breast cancer patients: preliminary analysis of an Intergroup study (INT0076). *J Natl Cancer Inst Monogr.* 11:167–72; 1992.

❖ **Dumitrescu RG, Cotarla I, Dumitrescu RG, Cotarla I:** Understanding breast cancer risk -- where do we stand in 2005? *Journal of Cellular & Molecular Medicine.* 9 (1):208-21; 2005.

❖ **Dupont WD, Page DL, Parl FF, et al.:** Long-term risk of breast cancer in women with fibroadenoma. *N Engl J Med* 331 (1): 10-5; 1994.

E

- ❖ **Easton DF:** Cancer risks in A-T heterozygotes. *Int J Radiat Biol* 66 (6 Suppl): S177-82; 1994.
- ❖ **Edwards JG, Swinson DEB, Jones JL, et al:** Tumor Necrosis Correlates with Angiogenesis and Is a Predictor of Poor Prognosis in Malignant Mesothelioma. *Chest*. 124:1916-23; 2003.
- ❖ **Eerola AK, Ruokolainen H, Soini Y, et al:** Accelerated apoptosis and low bcl-2 expression associated with neuroendocrine differentiation predict shortened survival in operated large cell carcinoma of the lung. *Pathol Oncol Res*. 5,179-86; 1999.
- ❖ **Eerola AK, Soini Y, and Pääkkö P:** A High Number of Tumor-infiltrating Lymphocytes Are Associated with a Small Tumor Size, Low Tumor Stage, and a Favorable Prognosis in Operated Small Cell Lung Carcinoma. *Clin. Cancer Res*. 6(5): 1875–81; 2000.
- ❖ **Eierman DF, ohnson JCE, Haskill JS:** Human monocyte inflammatory mediator gene expression is selectively regulated by adherence substrates. *J Immunol*. 142: 1970-6; 1989.
- ❖ **Elattar E:** The cancer database. *Egyptian Society of Surgical Oncology Conference*; 2005.
- ❖ **Elattar IA, Ali-eldin NH, Moneer MM, et al:** Cancer of breast. In *National Cancer Institute Registry*. pp. 45-6; 2003.
- ❖ **ElBolkainy M:** Breast cancer in Topographic pathology of cancer 2nd edition. *Al-Asdekaa Graphics Center Cairo*. p 81-88; 2000.
- ❖ **Elgert KD, Alleva DG, Mullins DW:** Tumor-induced immune dysfunction: the macrophage connection. *J Leukoc Biol*. 64:275-90; 1998.

- ❖ **Elledge RM, Green S, Howes L, et al:** bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. *J Clin Oncol.* 15:1916–22; 1997.
- ❖ **Elpek GÖ, Gelen T, Aksoy NH, et al:** The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. *J Clin Pathol.* 54:940-4; 2001.
- ❖ **Elston CW and Ellis IO:** Assessment of histologic grade. In: *Elston CW, Ellis IO, eds. Systemic Pathology. 3rd ed, vol 13. The Breast. Edinburgh, Scotland: Churchill Livingstone. 375–6; 1998.*
- ❖ **Elston CW and Ellis JO:** Pathological prognostic factors in breast cancer: experience from a long study with long-term follow up. *Histopathology.* 19:403–10; 1991.
- ❖ **Endogenous Hormones and Breast Cancer Collaborative Group:** Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *J Natl Cancer Inst* 94 (8): 606-16; 2002.
- ❖ **Erickson SL, de-Sauvage FJ, Kikly K, et al:** Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. *Nature.* 372: 560-3; 1994.
- ❖ **ESHRE Capri Workshop Group:** Hormones and breast cancer. *Hum Reprod Update.*10:281-93; 2004.
- ❖ **Esposito V, Baldi A, De Luca A, et al:** Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. *Cancer Res.* 57:3381–5; 1997.
- ❖ **Esteller M, Silva JM, Dominguez G, et al:** Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. *J Natl Cancer Inst.*92:564–9; 2000.

❖ **Etoh T, Shibuta K, Barnard GF, Kitano S and Mori M:** Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. *Clin Cancer Res* 6: 3545-51, 2000.

F

❖ **Feng HC, Song YF, Wen YM:** Correlation between expression of vascular endothelial growth factor-C in tumor-associated macrophages and lymphatic metastasis in oral cancer. *Ai Zheng. Mar*; 23(3):278-81, 2004.

❖ **Fentiman IS, Fourquet A, Hortobagyi GN, et al:** Male breast cancer. *Lancet*. 367(9510):595-604; 2006.

❖ **Feoktistov I, Ryzhov S, Goldstein AE, Biaggioni I:** Mast cell mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. *Circ Res*. 92: 485-92; 2003.

❖ **Ferrara N:** VEGF and the quest for tumour angiogenesis factors. *Nat Rev Cancer*.2:795–803; 2002.

❖ **Fidler IJ:** Eradication of cancer metastasis by tumoricidal macrophages. *Advances in Experimental Medicine & Biology*. 233: 415-23; 1988.

❖ **Fieren MW, van-den-Bemd GJ, Ben-Efraim S, Bonta IL:** Prostaglandin E2 inhibits the release of tumor necrosis factor-alpha, rather than interleukin 1 beta, from human macrophages. *Immunology Letters*. 31: 85-90; 1992.

❖ **Fina L, Molgaard HV, Robertson D, et al:** Expression of the CD34 gene in vascular endothelial cells. *Blood*.12:2417–26; 1990.

❖ **Fisher B, Bryant J, Wolmark N, et al:** Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. *J*

Clin Oncol. 16:2672–85; 1998.

❖ **Fisher ER, Anderson S, Redmond C, Fisher B:** Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06: 10-year pathologic and clinical prognostic discriminants. *Cancer.*71:2507–14; 1993.

❖ **Fisher ER, Anderson S, Tan-Chiu E, et al:** Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol 06. *Cancer.* 91: 1679- 88; 2001.

❖ **Fisher ER, Dignam J, Tan-Chiu E, et al:** Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. *Cancer* 86 (3): 429-38, 1999.

❖ **Fisher ER, Gregorio R, Redmond C, et al:** Pathologic findings from the national surgical adjuvant breast project. *Cancer.* 35: 247-54; 1975.

❖ **Fitzgibbons PL, Page DL, Weaver D, et al:** Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. *Arch Pathol Lab Med.* 124:966–78; 2000.

❖ **Foote RL, Weidner N, Harris J, et al:** Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: Results of RTOG 9505. *Int. J. Radiation Oncology Biol. Phys.* 61(3): 745–53, 2005.

❖ **Ford D, Easton DF, Peto J:** Estimates of the gene frequency of *BRCA1* and its contribution to breast and ovarian cancer incidence. *Am J Hum Genet.* 57:1457–62; 1995.

❖ **Ford D, Easton DF, Stratton M, et al:** Genetic heterogeneity and penetrance analysis of the *BRCA1* and *BRCA2* genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 62

(3): 676-89; 1998.

❖ **Forssell J, Öberg A, Henriksson ML, et al:** High Macrophage Infiltration along the Tumor Front Correlates with Improved Survival in Colon Cancer. *Clinical Cancer Research* 13, 1472-9; 2007.

❖ **Fox SB, Smith K, Hollyer J, et al:** The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. *Breast Cancer Res Treat.* 29:41–9; 1994.

❖ **Fratelli M, Gagliardini V, Galli G, et al:** Autocrine interleukin-1 beta regulates both proliferation and apoptosis in EL4-6.1 thymoma cells. *Blood.* 85: 3532-7; 1995.

❖ **Fredersdorf S, Burns J, Milne AM, et al:** High level expression of p27 (kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27 (kip1) and degree of malignancy in some human breast and colorectal cancers. *Proc Natl Acad Sci USA.* 94:6380–5; 1997.

❖ **Fregene A NL:** Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? *Cancer* 103(8), 1540-50; 2005.

❖ **Friedman LS, Gayther SA, Kurosaki T, et al:** Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. *Am J Hum Genet.* 60:313–9; 1997.

❖ **Fukumura D, Xavier R, Sugiura T, et al:** Tumor induction of VEGF promoter activity in stromal cells. *Cell* 94: 715-25; 1998.

❖ **Fuqua SA:** Coexpression of ER- α and ER- β in breast tumors. *B. J. Cancer.* 79: 1820-35; 2000.

❖ **Furberg H, Newman B, Moorman P, et al:** Lactation and breast

cancer risk. *Int J Epidemiol* 28 (3): 396-402; 1999.

G

❖ **Gargett CE, Zaitseva M, Bucak K, et al:** 17Beta-estradiol up-regulates vascular endothelial growth factor receptor-2 expression in human myometrial microvascular endothelial cells: role of estrogen receptor-alpha and -beta. *J Clin Endocrinol Metab.* 87:4341–9; 2002.

❖ **Gasparini G, Barbareschi M, Doglioni C, et al:** Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. *Clin Cancer Research* 1:189–98, 1995.

❖ **Gasparini G.:** Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer. *The Oncologist, Vol. 5, Suppl 1, 37-44, April, 2000.*

❖ **Gavin TP, Robinson CB, Yeager RC, et al:** Angiogenic growth factor response to acute systemic exercise in human skeletal muscle. *J App Physiol* 96: 19-24; 2004.

❖ **Gilchrist KW, Gray R, Fowble B, et al:** Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer. A 10-year follow up study of 728 Eastern Cooperative Oncology Group patients. *J Clin Oncol.* 11: 1929-35; 1993.

❖ **Gion M, Mione R, Dittadi R, et al:** Relationship between cathepsin D and other pathologic and biological parameters in 1752 patients with primary breast cancer. *Eur J Cancer.* 5:671–7; 1995.

❖ **Giraud E, Inoue M and Hanahan D:** An amino-bisphosphonate targets MMP-9- Expressing macrophages and angiogenesis to impair cervical carcinogenesis. *J. Clin. Invest.* 114: 623–633; 2004.

- ❖ **Gobbi H, Jensen RA, Simpson JF, et al:** Atypical hyperplasia and ductal carcinoma insitu of the breast associated with perineural invasion. *Hum Pathol.* 32: 785-90; 2001.
- ❖ **Goldstein NS:** Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases. *Am J Clin Pathol.* 118: 425-34; 2002.
- ❖ **Goldstein, NS, Mani, A, Chmielewski, G, et al:** Prognostic factors in T1N0M0 adenocarcinomas and bronchioloalveolar carcinomas of the lung. *Am J Clin Pathol.* 112, 391-402; 1999.
- ❖ **Gouon-Evans E, Lin EY and Pollard JW:** Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. *Breast Cancer Res* 2002, 4:155-64; 2002.
- ❖ **Goyert SM:** CD68: In: Protein Reviews On the Web. *Garland Press and by the International Workshops on Human Leukocyte Differentiation Antigens*; 1999.
- ❖ **Greaves MF, Brown J, Molgaard HV, et al:** Molecular features of CD34: a hemopoietic progenitor cell-associated molecule. *Leukemia.* 6: 31-6; 1992.
- ❖ **Griffioen AW, Damen CA, Martinotti S, et al:** Endothelial ICAM-1 expression is suppressed in human malignancies; role of angiogenic factors. *Cancer Res.* 56:1111–7; 1996.
- ❖ **Griffioen AW, Relou IAM, Gallardo Torres HI, et al:** The angiogenic factor bFGF impairs leukocyte adhesion and rolling under flow conditions. *Angiogenesis.* 2:45–50; 1999.
- ❖ **Grubbs CJ, Juliana MM, Hill DL and Whitaker M:** Chemically-induced mammary carcinogenesis. *Anticancer Res J.* 22 (1): 325-9; 2000.

- ❖ **Guang-Wu H, Sunagawa M, Jie-En L, et al:** The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. *Laryngoscope*.110:2066 –9; 2000.
- ❖ **Gumus M, Yumuk F, Salepci T, et al:** Human papilloma virus: Is it a new etiological factor in breast cancer? **Meeting: ASCO Annual Meeting**; Abstract No: 9635; 2004.
- ❖ **Guo Y, Lubbert M, Engelhardt M:** CD34- hematopoietic stem cells: current concepts and controversies. *Stem Cells*. 21:15-20; 2003.
- ❖ **Gusterson BA, Gelber RD, Goldhirsch A, et al:** Prognostic importance of c-erbB-2 expression in breast cancer. *J Clin Oncol*.10:1049–56; 1992.

H

- ❖ **Haas TL, Milkiewicz M, Davis SJ, et al:** Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. *Am J Physiol Heart Circ Physiol* 279: H1540-H1547; 2000.
- ❖ **Hagemann T, Robinson SC, Schulz M, et al:** Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF- α dependent up-regulation of matrix metalloproteases. *Carcinogenesis*. 25(8):1543-9; 2004.
- ❖ **Hahn WC and Weinberg RA:** Rules of making human tumor cells. *N Engl J Med*. 347: 1593; 2002.
- ❖ **Hall JM, Lee MK, Newman B, et al:** Linkage of early-onset familial breast cancer to chromosome 17q21. *Science*. 250:1684–9; 1990.
- ❖ **Hamajima N, Hirose K, Tajima K, et al:** Alcohol, tobacco and breast

cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. *Br J Cancer* 87 (11): 1234-45; 2002.

❖ **Hanada T, Nakagawa M, Emoto A, et al:** Prognostic value of tumour-associated macrophage count in human bladder cancer. *Int J Urol* 7 (7): 263-9; 2000.

❖ **Hanahan D and Weinberg RA:** The hallmarks of cancer. *Cell*. 100: 57; 2000.

❖ **Hansen S, Grabau DA, Rose C, Bak M, Sorensen FB:** Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. *Lab Invest*. 78:1563–73; 1998.

❖ **Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K:** Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. *J Immunol*. 156: 42-7; 1996.

❖ **Harris J, Morrow M, Bonadonna G:** Cancer of the breast. In: DeVita V, Hellman S, Rosenberg S (eds) *Cancer: Principles and practice of oncology*, 4th ed. Lippincott, Philadelphia, 1264-12; 1993.

❖ **Harris M, Howell A, Chrissohou M, et al:** A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. *Br J Cancer*. 50: 23; 1984.

❖ **Harris W and Helman IW:** Spread of mammary carcinoma. *Pathol Res Pract J*. 189 (9): 996- 1003; 1996.

❖ **Harvey JN, Clark GM, Osborne CK, Allred DC:** Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol*.17:1474–81; 1999.

- ❖ **Harvie M, Howell A, Vierkant RA, Kumar N, et al:** Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. *Cancer Epidemiol Biomarkers Prev.*14:656-61; 2005.
- ❖ **Hasebe T, Sasaki S, Imoto S, Ochiai A:** Histological characteristics of tumor in vessels and lymph nodes are significant predictors of progression of invasive ductal carcinoma of the breast: A prospective study. *Hum Pathol.*35:298-308; 2004.
- ❖ **Hashimoto I, Kodama J, Seki N, et al:** Macrophage infiltration and angiogenesis in endometrial cancer. *Anticancer Res.* 20(6C):4853-6; 2000.
- ❖ **Hayes DF, Yamauchi H, Broadwater G, et al:** Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. *Clin Cancer Res. Sep;* 7(9): 2703-11; 2001
- ❖ **Hedenfalk I, Duggan D, Chen Y, et al:** Gene-expression profiles in hereditary breast cancer. *N Engl J Med.*344:539–48; 2001.
- ❖ **Hedley DW, Clark GM, Cornelisse CJ, et al:** Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. *Cytometry.* 14:482–5; 1993.
- ❖ **Heimann T, Ferguson D, Powers C, et al:** Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. *J Natl Cancer Inst.* 88:1764–6; 1996.
- ❖ **Hellemans P, van Dam PA, Weyler J, et al:** Prognostic value of bcl-2 expression in invasive breast cancer. *Br J Cancer.* 72:354–60; 1995.
- ❖ **Hellwig SMM, Damen CA, Van Adrichem NPH, et al:** Endothelial CD34 is suppressed in human malignancies; role of angiogenic factors.

Cancer Lett. 120:203–11; 1997.

❖ **Helzlsouer KJ, Harris EL, Parshad R, et al:** DNA repair proficiency: potential susceptibility factor for breast cancer. *J Natl Cancer Inst* 88 (11): 754-5; 1996.

❖ **Helzlsouer KJ, Harris EL, Parshad R, et al:** Familial clustering of breast cancer: possible interaction between DNA repair proficiency and radiation exposure in the development of breast cancer. *Int J Cancer* 64 (1): 14-7; 1995.

❖ **Hemmerlein B, Scherbening J, Kugler A and Radzun HJ:** Expression of VCAM-1, ICAM-1, E- and P-selectin and tumour-associated macrophages in renal cell carcinoma. *Histopathology.* 37 (1), 78–83; 2000.

❖ **Henson DE, Ries L, Freedman LS, Carriaga M:** Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. *Cancer.* 68: 2142–9; 1991.

❖ **Herman CJ, Duque RE, Hedley D, et al:** DNA cytometry in cancer prognosis. *Principles Pract Oncol PPO Updates.* 7:1–8; 1993.

❖ **Heron DE, Komarnicky LT, Hyslop T, et al:** Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. *Cancer* 88 (12): 2739-50; 2000.

❖ **Herrada J, Hughes P, Buzdar A:** Early-Stage Breast Cancer and Adjuvant Therapy. *Medical Oncology*; 1997.

❖ **Hibbs JB, Taintor RR, Vavrin Z, Rachlin EM:** Nitric oxide: a cytotoxic activated macrophage effector molecule. *Biochem Biophys Res Commun.* 157: 87-94; 1988.

❖ **Hibbs JB:** The macrophage as a tumoricidal effector cell: a review of

in vitro and in vivo studies on the mechanism of the activated macrophage nonspecific cytotoxicity reaction. *New York, Academic Press*, 1976.

❖ **Hirokawa M, Sugihara K, Sai T, et al:** Secretory carcinoma of the breast: a tumour analogous to salivary gland acinic cell carcinoma? *Histopathology* 40(3):223-9; 2002.

❖ **Hisada M, Garber JE, Fung CY, et al:** Multiple primary cancers in families with Li-Fraumeni syndrome. *J Natl Cancer Inst* 90 (8): 606-11; 1998.

❖ **Holland R, Petersee J, Mills R, et al:** Ductal carcinoma in situ: a proposal for a new classification. *Semin Diagn Pathol.* 11: 167- 80; 1994.

❖ **Hollstein M, Sidransky D, Vogelstein B, et al:** p53 mutations in human cancers. *Science.* 253:49–53; 1991.

❖ **Hortobagyi GN, Kau SW, Buzdar AU, et al:** What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? *ASCO Annual Meeting. Abstract No. 585.* 2004.

❖ **Hunter DJ, Spiegelman D, Adami HO, et al:** Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. *N Engl J Med* 334 (6): 356-61; 1996.

❖ **Hurlimann J, Chaubert P, Benhattar J:** p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. *Mod Pathol.* 7:423–8; 1994.

I

❖ **Ibelgaufits H:** Angiogenesis. In *Horst Ibelgaufits' COPE: Cytokines &*

Cells Online Pathfinder Encyclopaedia; 2006.

❖ **Igarashi M, Dhar KD, Kubota H, et al:** The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. *Cancer*. 82:1225–35; 1998.

❖ **Ikpatt OF, Kuopio T, Collan Y:** Proliferation in African breast cancer: biology and prognostication in Nigerian breast cancer material. *Mod Pathol*. Aug; 15(8):783-9; 2002.

❖ **International (Ludwig) Breast Cancer Study Group:** Prognostic importance of occult axillary lymph node micrometastases from breast cancers. *Lancet*. 335:1565–8; 1990.

❖ **International Agency for Research on Cancer:** Hormonal contraceptive, progestogens only. In: IARC Monographs on the evaluation of carcinogenic risks to humans Vol.72 hormonal contraception and postmenopausal hormonal therapy. *IARC Press: Lyon*: 339-97; 1999a.

❖ **International Agency for Research on Cancer:** oral contraceptives, combined. In: IARC Monographs on the evaluation of carcinogenic risks to humans Vol.72 hormonal contraception and postmenopausal hormonal therapy. *IARC Press: Lyon*: 49-338; 1999b.

❖ **International Agency for Research on Cancer:** Post-menopausal estrogen-progesterone therapy. In: IARC Monographs on the evaluation of carcinogenic risks to humans Vol.72 hormonal contraception and postmenopausal hormonal therapy. *IARC Press: Lyon*: 531-628; 1999c.

❖ **International Agency for Research on Cancer:** Post-menopausal estrogen therapy. In: IARC Monographs on the evaluation of carcinogenic risks to humans Vol.72 hormonal contraception and postmenopausal hormonal therapy. *IARC Press: Lyon*: 399-530; 1999d.

- ❖ **Ioakim-Liossi A, Karakitsos P, Markopoulos C, et al:** p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas. *Cytopathology*. 12:197–202; 2001.
- ❖ **Iqbal M, Davies MP, Shoker BS, et al:** Subgroups of non-atypical hyperplasia of breast defined by proliferation of estrogen receptor positive cells. *J Pathol*. 193: 333; 2001.
- ❖ **Itoh K, Platsoucas CD, Balch CM:** Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cells. *Cellular Immunology*. 108: 495-500; 1987.

J

- ❖ **Jatoi I, Hilsenbeck G, Clark GM and Osbrone K:** Significance of axillary lymph node metastasis in primary breast cancer. *J Clin Oncol*. 7 (8): 2334-410; 1999.
- ❖ **Jensen RA and PageDL:** Ductal carcinoma insitu of the breast. Impact of pathology on therapeutic decision. *Am J Surg Pathol*. 27: 828-31; 2003.
- ❖ **Jernström H, Lubinski J, Lynch HT, et al:** Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 96 (14): 1094-8; 2004.
- ❖ **Jimenez RE, Wallis T, Visscher DW:** Centrally necrotizing carcinomas of the breast: a distinct histologic subtype with aggressive clinical behavior. *Am J Surg Pathol*. 25: 331-7, 2001.
- ❖ **Jitsuiki, Y, Hasebe, T, Tsuda, H, et al:** Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast. *Mod Pathol*. 12,492-8; 1999.

- ❖ **Johnston SR, Head J, Pancholi S, et al:** Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. *Clin Cancer Res.* 9:524S–532S; 2003.
- ❖ **Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V:** Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. *Am J Pathol* 158(1):207-14; 2001.
- ❖ **Judy AK, Solomon F, Troy S, Al-Mehdi A, et al:** Activated Leukocyte Cell Adhesion Molecule in Breast Cancer: Prognostic Indicator. *Breast Cancer Res* 6(5):478-87; 2004.

K

- ❖ **Kaaks R, Lundin E, Manjer J, et al:** Prospective study of IGF-1, IGF-binding proteins and breast cancer risk, in northern and southern Sweden. *Cancer Causes Control.* 13: 307-16; 2002.
- ❖ **Kainu T, Juo SH, Desper R, et al:** Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. *Proc Natl Acad Sci U S A.* 97:9603-8; 2000.
- ❖ **Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al:** Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. *BMC Cancer.* 5: 25; 2005.
- ❖ **Kastan M:** Ataxia-telangiectasia--broad implications for a rare disorder. *N Engl J Med* 333 (10): 662-3; 1995.
- ❖ **Kato T, Kameoka S, Kimura T, et al:** P53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer. *Anticancer Res.*; 22:1105–12, 2002.

-
- ❖ **Kato T, Kameoka S, Kimura T, et al:** The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. *British Journal of Cancer* 88, 1900-8, 2003.
- ❖ **Kelsey JL and Gammon MD:** The epidemiology of breast cancer. *CA Cancer J Clin* 41 (3): 146-65; 1991.
- ❖ **Kelsey JL and Horn-Ross PL:** Magnitude of the problem and descriptive epidemiology. *Hygiene and Public Health* 7-16; 1993.
- ❖ **Kerangueven F, Essioux L, Dib A, et al:** Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. *Oncogene*.10:1023–6; 1995.
- ❖ **Kerlikowske K, Shepherd J, Creasman J, et al:** Are breast density and bone mineral density independent risk factors for breast cancer? *J Natl Cancer Inst.* 97: 368-74; 2005.
- ❖ **Kerns BJ, Jordan PA, Moore MB, et al:** p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. *J Histochem Cytochem.* 40: 1047–51; 1992.
- ❖ **Keshgegian AA and Cnaan A:** Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. *Am J Clin Pathol.* 104: 42–9; 1995.
- ❖ **Kessler, R, Gasser, B, Massard, G, et al:** Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. *Ann Thorac Surg.* 62: 1489-93; 1996.
- ❖ **Key TJ, Appleby PN, Reeves GK, et al.:** Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. *J Natl Cancer Inst* 95 (16): 1218-26; 2003.

- ❖ **Key TJ, Verkasalo PK, Banks E, et al:** Epidemiology of breast cancer. *Lancet Oncol.* 2:133; 2001.
- ❖ **Keyomarsi K, Tucker SL, Buchholz TA, et al:** Cyclin E and survival in patients with breast cancer. *N Engl J Med.* 347:1566–75; 2002.
- ❖ **Khanna KK:** Cancer risk and the ATM gene: a continuing debate. *J Natl Cancer Inst.* 92:795–802; 2000.
- ❖ **Khanuja PS, Fregene T, Gimotty P, et al:** Angiogenesis does not predict recurrence in patients with primary breast cancer. *Proc Am Soc Clin Oncol.* 12: 67; 1993.
- ❖ **Killion JJ and Fidler IJ:** Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators. *Pharmacology & Therapeutics.* 78: 141-54; 1998.
- ❖ **Kim H and Muller WJ:** The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. *Exp Cell Res.* Nov 25; 253(1): 78-87; 1999
- ❖ **Kimura S, Sone S, Takahashi K, et al:** Antitumour potential of pleural cavity macrophages in lung cancer patients without malignant effusion. *British Journal of Cancer.* 59: 535-9; 1989.
- ❖ **Kindblom LG, Remotti HE, Aldenborg F, and Meis-Kindblom JM:** Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. *Am. J. Pathol;* 152; 1259–69, 1998.
- ❖ **Kirby I and Bland EA:** The Breast. *Schwartz's Principles of Surgery* 8th edition; 2007.
- ❖ **Kleihues P, Schäuble B, zur Hausen A, et al:** Tumors associated with p53 germline mutations: a synopsis of 91 families. *Am J Pathol* 150 (1):

1-13; 1997.

- ❖ **Kleinberg, et al:** *Br. J. Cancer Res. Treat.*, vol. 47, pp. 201-8, 1998.
- ❖ **Knudson AG Jr:** Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci USA*. 68:820–3; 1971.
- ❖ **Koch AE, Polverini PJ, Kunkel SL, et al:** Interleukin-8 as a macrophage-derived mediator of angiogenesis. *Science* 258: 1798-801, 1992.
- ❖ **Kollias J, Elston CE, Ellis IO, Robertson JFR, and Blamey RW:** Early-onset breast cancer: histopathological and prognostic considerations. *Br J Cancer*. 75: 1318–23; 1997.
- ❖ **Koukourakis MI, Giatromanolaki A, Kakolyris S, et al:** Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. *Br J Cancer* 77: 1696-703, 1998.
- ❖ **Krag DN, Weaver DL, Alex JC, Fairbank JT:** Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. *Surg Oncol*. 2:335–340; 1993.
- ❖ **Kraus RM, Stallings HW, Yeager RC& Gavin TP:** Circulating plasma VEGF response to exercise in sedentary and endurance-trained men. *J App Physiol* 96: 1445-50; 2004.
- ❖ **Krause DS, Fackler MJ, Civin CI and May WS:** CD34: structure, biology, and clinical utility. *Blood*. 87 (1): 1-13; 1996.
- ❖ **Kunisch E, Fuhrmann R, Roth A, et al:** Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. *Annals of the Rheumatic Diseases*. 63:774-84; 2004.

- ❖ **Kunz-Schughart LA and Knuechel R:** Tumor-associated fibroblasts (part I) active stromal participants in tumor development and progression? *Histol Histopathol.* 17:599–621; 2002a.
- ❖ **Kunz-Schughart LA and Knuechel R:** Tumor-associated fibroblasts (part II) functional impact on tumor tissue. *Histol Histopathol.* 17:623–37; 2002b.
- ❖ **Kwon GY, Lee S, and Park E:** Mast cell and macrophage counts and microvessel density in invasive breast carcinoma-comparison analysis with clinicopathological parameters. *Cancer Res Treat.* 37 (2): 103-8; 2005.

L

- ❖ **Lah TT, Kalman E, Najjar D, et al:** Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis. *Hum Pathol.* 31: 149- 60; 2000.
- ❖ **Lahmann PH, Gullberg B, Olsson H, et al:** Birth weight is associated with postmenopausal breast cancer risk in Swedish women. *British Journal of Cancer.* 91: 1666-8; 2004.
- ❖ **Lambe M, Hsieh C, Trichopoulos D, et al:** Transient increase in the risk of breast cancer after giving birth. *N Engl J Med* 331 (1): 5-9; 1994.
- ❖ **Lane DP, Lu X, Hupp T, et al:** The role of the p53 protein in the apoptotic response. *Philos Trans R Soc Lond B Biol Sci.* 345:277–80; 1994.
- ❖ **Lange C, Li Z, Fang L, et al:** CD34 Modulates the trafficking behavior of hematopoietic cells in vivo. *Stem Cells Dev.* 16 (2):297-304; 2007.

- ❖ **Lanza F, Healy L, Sutherland DR:** Structural and functional features of the CD34 antigen: an update. *J Biol Regul Homeost Agents*. 15: 1-13; 2001.
- ❖ **Lara JF, Young SM, Velilla RE, et al:** The relevance of occult axillary micrometastasis in ductal carcinoma in situ. A clinicopathological study with long-term follow-up. *Cancer*. 98: 2105-13; 2003.
- ❖ **Lazennec R, Rorlly J and Paunel B:** Relation of estrogen receptors expression and breast carcinoma. *Oncogene*. 410: 82-9; 2001.
- ❖ **LeDoussal V, Tubiana-Hulin M, Friedmans Brunet M:** Mitotic activity index in invasive ductal carcinoma. *Cancer J*. 64: 1914-21; 1999.
- ❖ **Lee A, Happerfield LC, Bobrow LG and Millis RR:** Angiogenesis and inflammation in invasive carcinoma of the breast. *J Clin Pathol* 50: 669-73; 1997a.
- ❖ **Lee A, Happerfield LC, Bobrow LG, Millis RR:** Angiogenesis and inflammation in ductal carcinoma in situ of the breast. *J Pathol*. 181:200-6; 1997 b.
- ❖ **Lee AH, Dublin EA, Bobrow LG:** Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. *J Pathol*.187:285–90; 1999.
- ❖ **Lee JS, Kim HS, Jung JJ, Kim YB, Lee MC, Park CS:** Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression. *Appl Immunohistochem Mol Morphol*. 10: 289–95; 2002.
- ❖ **Lee WH, Bookstein R, Hong F, et al:** Human retinoblastoma susceptibility gene: cloning, identification, and sequence. *Science*.235:1394–9; 1987.

- ❖ **Leek RD and Harris AL:** Tumor associated macrophages in breast cancer. *J Mammary Gland Biol Neoplasia*; 7 (2): 177-89, 2002.
- ❖ **Leek RD, Landers R, Harris A, Lewis C:** Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. *Br J Cancer*. 79(5-6): 991-5, 1999.
- ❖ **Leek RD, Lewis CE, Whitehouse R, et al:** Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. *Cancer Res*. 56: 4625-9; 1996.
- ❖ **Leek RD, Talks KL, Pezzella F, et al:** Relation of Hypoxia-inducible Factor-2 (HIF-2 α) Expression in Tumor-infiltrative Macrophages to Tumor Angiogenesis and the Oxidative Thymidine Phosphorylase Pathway in Human Breast Cancer. *Cancer Research*. 62, 1326-9; 2002.
- ❖ **Leist M, Gantner F, Jilg S, Wendel A:** Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. *Journal of Immunology*. 154: 1307-16; 1995.
- ❖ **Leitzel K, Teramoto Y, Konrad K, et al:** Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. *J Clin Oncol*. 13:1129–35; 1995.
- ❖ **Lepoivre M, Flaman JM, Henry Y:** Early loss of the tyrosyl radical in ribonucleotide reductase of adenocarcinoma cells producing nitric oxide. *Journal of Biological Chemistry*. 267: 2294-3000; 1992.
- ❖ **Lester SC:** The breast. In *Cotran RS, Kumar V, Robbins SL: pathologic Basis of Diseases. Ch 25, 7th ed. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: WB Saunders Company: 1119-45; 2005.*
- ❖ **Levine AJ:** p53, the cellular gatekeeper for growth and division. *Cell*.

88:323–31; 1997.

❖ **Lewis JS, Landers RJ, Underwood JCE, et al:** Expression of vascular endothelial growth factor by macrophage is up-regulated in poorly vascularized areas of breast carcinomas. *J Pathol* 192: 150-8; 2000.

❖ **Lewis JS, Lee JA, Underwood JCE, et al:** Macrophage response to hypoxia: relevance to disease mechanisms. *J Leukoc Biol* 66: 889-900; 1999.

❖ **Li FP:** Familial cancer syndromes and clusters. *Curr Probl Cancer*. 14:73–114; 1990.

❖ **Li G, Satyamoorthy K, Meier F, et al:** Function and regulation of melanoma-stromal fibroblast interactions when seeds meet soil. *Oncogene*.22:3162–7; 2003.

❖ **Li WW:** Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. *Acta Radiol* 7:800-11, 2000.

❖ **Lissbrant IF, Stattin P, Wikstrom P, et al:** Tumour associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. *Int J Oncol* 17: 445-51; 2000.

❖ **Liu E, Thor A, He M, et al:** The HER-2 (c-erbB-2) oncogene is frequently amplified in insitu carcinomas of the breast. *Oncogene*. 7:1027–32; 1992.

❖ **Llombart-Bosch A, Contesso G, Henry-Amar M, et al:** Histopathological predictive factors in Ewing's sarcoma of bone and clinicopathological correlations: a retrospective study of 261 cases. *Virchows Arch A Pathol Anat Histopathol*. 409: 627-40; 1986.

❖ **Lloyd PG, Prior BM, Yang HT& Terjung RL:** Angiogenic growth factor expression in rat skeletal muscle in response to exercise training.

Am J Physiol Heart Circ Physiol 284: 1668-78; 2003.

❖ **Loda M, Cukor B, Tam SW, et al:** Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. *Nat Med.* 3:231–4; 1997.

❖ **Loden M, Stighall M, Nielsen NH, et al:** The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node. *Oncogene.* 21:4680–90; 2002.

❖ **Losordo DW and Isner JM:** Estrogen and angiogenesis: a review. *Arterioscler Thromb Vasc Biol.* 21: 6–12; 2001.

❖ **Lukas J, Niu N and Press MF:** p53 Mutations and Expression in Breast Carcinoma in Situ. *American Journal of Pathology.* 156:183-91; 2000.

❖ **Lynch OR, Kohn KW and Galvano JE:** Cowden's disease. *Pathol J.* (6): 120-7; 1998.

M

❖ **Ma`kitie T, Summanen P, Tarkkanen A and Kivela T:** Tumor-Infiltrating Macrophages (CD681 Cells) and Prognosis in Malignant Uveal Melanoma. *Invest Ophthalmol Vis Sci.* 42:1414–21; 2001.

❖ **Ma`kitie T, Summanen P, Tarkkanen A and Kivela` T:** Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. *Invest Ophthalmol Vis Sci.* 40: 2471–80; 1999.

❖ **MacMahon B:** Epidemiology and the causes of breast cancer. *International Journal of Cancer.* 118(10):2373-8; 2006.

- ❖ **Magro G, Michal M, Bisceglia M:** Benign spindle cell tumours of the mammary stroma: diagnostic criteria, classification and histogenesis. *Pathol Res Pract.*197:453–66; 2001.
- ❖ **Malkin D, Li FP, Strong LC, et al:** Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science.* 250:1233–8; 1990.
- ❖ **Malone KE, Daling JR, Thompson JD, et al:** BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. *JAMA* 279 (12): 922-9; 1998.
- ❖ **Manders P, Bult P, Sweep CG, et al:** The prognostic value of the mitotic activity index in patients with primary breast cancer who were not treated with adjuvant systemic therapy. *Breast Cancer Res. Treat;* 77:77–84, 2003.
- ❖ **Mandicæ A, Vujkov T, Ninèlææ D and Komazec S:** Tumor angiogenesis and endometrial cancer. *Archive of Oncology.* 10(2):79-81; 2002.
- ❖ **Mansour EG, Ravdin PM, Dressler L:** Prognostic factors in early breast cancer. *Cancer.* 74: 381–400; 1994.
- ❖ **Mantovan, A, Bottazzi B, Colotta F, Sozzani S, Ruco L:** The origin and function of tumor-associated macrophages. *Immunol Today.* 13:265-70; 1992.
- ❖ **Mantovani A:** Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. *Lab Invest.* 71:5–16; 1994.
- ❖ **Marino PA and Adams DO:** Interaction of Bacillus Calmette-Guerin-activated macrophages and neoplastic cells in vitro. I. Conditions of

binding and its selectivity. *Cellular Immunology*. 54: 11-25; 1980.

❖ **Marino PA, Whisnant CC, Adams DO:** Binding of bacillus Calmette-Guerin-activated macrophages to tumor targets. Selective inhibition by membrane preparations from homologous and heterologous neoplastic cells. *J Exp Med*. 154: 77-87; 1981.

❖ **Martin AM and Weber BL:** Genetic and hormonal risk factors in breast cancer. *J Natl Cancer Inst*. 92:1126-35; 2000.

❖ **Mashimo T, Watabe M, Hirota S, et al:** The expression of the *KAI1* gene, a tumor metastasis suppressor, is directly activated by p53. *Proc Natl Acad Sci USA*. 95:11307–11; 1998.

❖ **McDonald JA, Mandel MG, Marchbanks PA, et al:** Alcohol exposure and breast cancer: results of the women's contraceptive and reproductive experiences study. *Cancer Epidemiol Biomarkers Prev*. 13: 2106-16; 2004.

❖ **McDonnell DP, Clemm DL, Hermann T:** Analysis of the estrogen receptor function in vitro reveals three distinct classes of antiestrogen. *Mol Endocrinol*. 9: 659; 1995.

❖ **McGuire WL and Clark GM:** Prognostic factors and treatment decisions in axillary-node-negative breast cancer. *N Engl J Med* 326: 1756–61; 1992.

❖ **McGuire WL:** Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. *J Clin Oncol* 6:1071–2; 1988.

❖ **McPherson K, Steel CM, Dixon JM:** ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. *BMJ*. 321(7261): 624-8; 2000.

- ❖ **Medri L, Volpi A, Nanni O, Vecchi AM, et al:** Prognostic relevance of mitotic activity in patients with node-negative breast cancer. *Mod Pathol.* 16(11):1067-75; 2003.
- ❖ **Meyer JS, Alvarez C, Milikowski C, et al:** Breast carcinoma malignancy grading by Bloom-Richardson system vs. proliferation index: reproducibility of grade and advantages of proliferation index. *Mod Pathol.* 18(8):1067-78; 2005.
- ❖ **Mezi S, Aloise G, Marzulla A, et al:** Prognostic significance of desmoplasia in breast carcinoma. A preliminary clinical study. *Giornale Di Chirurgia.* 18 (5): 263-8; 1997.
- ❖ **Middleton LP, Vlastos G, Mirza NQ, et al:** Multicentric mammary carcinoma: evidence of monoclonal proliferation. *Cancer.* 94: 1910-6; 2002.
- ❖ **Miki Y, Swensen J, Shattuck-Eidens D, et al:** A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science.* 266:66–71; 1994.
- ❖ **Mills GB, Lu Y, Fang X, et al:** The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. *Semin Oncol.* 28(suppl 16):125–41; 2001.
- ❖ **Mineo TC, Ambrogi V, Baldi A, et al:** Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumor vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. *Clin Pathol.* 2004 Jun; 57(6):591-7, 2004.
- ❖ **Mita MM, Mita A, Rowinsky EK:** Mammalian target of rapamycin: a new molecular target for breast cancer. *Clin Breast Cancer.* 4:126–37; 2003.

- ❖ **Mohsin SK, Weiss H, Havighurst T, et al:** Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. *Mod Pathol*. 17(12):1545-54; 2004.
- ❖ **Mokhtar N:** Cancer Pathology Registry. Cairo, Egypt, National Cancer Institute. pp. 10-26; 1998.
- ❖ **Molino A, Micciolo R, Turazza M, et al:** Ki-67 immunostaining in 322 primary breast cancers: association with clinical and pathological variables and prognosis. *Int J Cancer*. 74:433–7; 1997.
- ❖ **Moore T and Lee AHS:** Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast. *Histopathology*. 38: 62–76; 2001.
- ❖ **Morimoto LM, White E, Chen Z, et al:** Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). *Cancer Causes Control* 13 (8): 741-51; 2002.
- ❖ **Morris SMJ and Billiar TR:** New insights into the regulation of inducible nitric oxide synthesis. [Review] [102 refs]. *American Journal of Physiology*. 266, E829-39; 1994.
- ❖ **Muir D, Kanthan R, Kanthan SC:** Male versus Female Breast Cancers. *Arch Pathol Lab Med*. 127(1):36-41; 2003.
- ❖ **Murdoch C, Giannoudis A and Lewis CE:** Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. *Blood*. 104: 2224–34; 2004.
- ❖ **Muro-Cacho CA, Cantor AB, Morgan M:** Prognostic factors in malignant gastrointestinal stromal tumors. *Ann Clin Lab Sci*. 30:239-47; 2000.
- ❖ **Mytar B, Siedlar M, Woloszyn M, et al:** Induction of reactive oxygen

intermediates in human monocytes by tumour cells and their role in spontaneous monocyte cytotoxicity. *British Journal of Cancer*. 79: 737-43; 1999.

N

❖ **Nagata C, Mizoue T, Tanaka K, et al:** Tobacco smoking and breast cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. *Japanese Journal of Clinical Oncology*. 36(6): 387-94; 2006.

❖ **Nahta R, Hortobagyi GN, Esteva FJ:** Growth factor receptors in breast **cancer**: potential for therapeutic intervention. *The Oncologist*. 8:5–17; 2003.

❖ **Nakopoulou LL, Alexiadou A, Theodoropoulos GE, et al:** Prognostic significance of the coexpression of p53 and c-erbB-2 protein in breast cancer. *J Pathol*. 179: 31-8; 1996.

❖ **Nandi, et al:** *Proc. Natl. Acad. Sci. USA*, vol. 92, pp. 3650-7; 1995.

❖ **Narod SA, Dubé MP, Klijn J, et al:** Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 94 (23): 1773-9; 2002.

❖ **Nass SJ and Davidson NE:** The biology of breast cancer. *Hematol Oncol Clin North Am*. Apr; 13(2): 311-32; 1999.

❖ **Nass SJ and Dickson RB:** Defining a role for c-myc in breast tumorigenesis. *Breast Cancer Res Treat*. 44:1–22; 1997.

❖ **Nathan C:** Natural resistance and nitric oxide. *Cell*. 82: 873-6; 1995.

❖ **National Co-ordinating Group for breast screening pathology:** Pathology reporting. In: *Breast Screening Pathology*, 2nd ed. Ed. NHSPSP

Publications; 1995.

❖ **Natkunam Y, Rouse RV, Zhu S, et al:** Immunoblot analysis of CD34 expression in histologically diverse neoplasms. *Am. J. Pathol.*; 56; 21–7, 2000.

❖ **Navarro S, Debili N, Bernaudin JF, et al:** Regulation of the expression of IL-6 in human monocytes. *J Immunol.* 142: 4339-45; 1989.

❖ **Neal CP and Berry DP:** Basic principles of the molecular biology of cancer II: angiogenesis, invasion and metastasis. *Surgery (Oxford).* 24(4): 120-5; 2006.

❖ **Nelen MR, van Staveren WC, Peeters EA et al:** Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. *Hum Mol Genet.*6:1383–7; 1997.

❖ **Neville AM, Bettelheim R, Gelber RD, et al:** Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. *J Clin Oncol.* 10:696–705; 1992.

❖ **Newman LA, Carolin K, Simon M, et al:** Impact of breast carcinoma on African-American women: the Detroit experience. *Cancer.* 91(9):1834-43; 2001.

❖ **Nicholson RI and Gee JM:** Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. *Br J Cancer.* Feb; 82(3): 501-13; 2000.

❖ **Nicholson S, Wright C, Sainsbury JRC, et al:** Epidermal growth factor receptor (EGFR) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. *J Steroid Biochem Molec Biol.* 37:811–4; 1990.

❖ **Nishie A, Ono M, Shono T, et al:** Macrophage infiltration and heme

oxygenase-1 expression correlate with angiogenesis in human gliomas. *Clin Cancer Res* 5: 1107-13; 1999.

❖ **Noel A, Kebers F, Maquoui E, Foidart JM:** Cell-cell and cell-matrix interactions during breast cancer progression. *Curr Top Pathol.* 93: 183–93; 1999.

❖ **Noguchi S, Aihara T, Nakamori S, et al.** The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. *Cancer.* 74:1595–600; 1994.

❖ **Normanno N, Ciardiello F, Brandt R, Salomon DS:** Epidermal growth factor related peptides in the pathogenesis of human breast cancer. *Breast Cancer Res Treat.* 29:11–27; 1994.

❖ **Norton J, Sloane JP, Delia D, Greaves MF:** Reciprocal expression of CD34 and cell adhesion molecule ELAM- 1 on vascular endothelium in acute cutaneous graft-versus- host disease. *J Pathol.* 170: 173-7; 1993.

❖ **Nowell PC:** The clonal evolution of tumor cell populations. *Science.* 194: 23–8; 1976.

O

❖ **O’Connell P, Pekkel V, Fuqua SA, et al:** Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. *J Natl Cancer Inst.* 90:697–703; 1998

❖ **Oberg A, Samii S, Stenling R and Lindmark G:** Different occurrence of CD8⁺, CD45R0⁺, and CD68⁺ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. *Int. J. Colorectal Dis.* 17: 25–9; 2002.

❖ **O'Donoghue AE, Poller DN, Bell JA, et al:** Cathepsin D in primary

breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. *Breast Cancer Res Treat.* 33:137–45; 1995.

❖ **Okobia MN, Bunker CH, Okobia MN, and Bunker CH:** Estrogen metabolism and breast cancer risk. *African Journal of Reproductive Health.* 10(1):13-25; 2006.

❖ **Olewniczak S, Chosia M, Kwas A, et al:** Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. *Pol J Pathol.* 53:183– 8; 2002.

❖ **Omar S, Shahbender S, Osman A, et al:** Breast cancer: In treatment Policy in NCI ed. ElBolkainy MN. pp. 11-9. *NCI, Cairo;* 1994.

❖ **Omar S, Khaled H, Gaafar R, Zekry AR, Eissa S, el-Khatib O, et al:** Breast cancer in Egypt: a review of disease presentation and detection strategies. *Eastern Mediterranean Health Journal.* 9(3):448-63; 2003.

❖ **Onland-Moret NC, Kaaks R, van Noord PA, et al:** Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. *Br J Cancer* 88 (9): 1394-9; 2003.

❖ **Ono M, Torisu H, Fukushi J, Nishie A, Kuwano M:** Biological implications of macrophage infiltration in human tumor angiogenesis. *Cancer Chemother Pharmacol.* 43: S69-71; 1999.

❖ **Ophascharoensuk V, Fero ML, Hughes J, et al:** The cyclin-dependent kinase inhibitor p27^{Kip1} safeguards against inflammatory injury. *Nat Med.* 4:575–80; 1998.

❖ **Orre M and Rogers PAW:** Macrophages and microvessel density in tumors of the ovary. *Gynecol Oncol* 73: 47-50, 1999.

❖ **Osborne C, Wilson P and Tripathy D:** Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic

Applications. *The Oncologist*. 9 (4): 361–77; 2004.

❖ **Osin P, Lu Y-J, Stone J, et al:** Distinct genetic and epigenetic changes in medullary breast cancer. *Int J Surg Pathol*. 11: 153-8; 2003.

❖ **Otis CN, Krebs PA, Albuquerque A, et al:** Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features. *Int J Surg Pathol*. 10: 237-45; 2002.

❖ **Oved S and Yarden Y:** Signal transduction: molecular ticket to enter cells. *Nature*. 416:133–6; 2002.

P

❖ **Page DL, Jensen RA, Simpson JF:** Routinely available indicators of prognosis in breast cancer. *Br Cancer Res Treat*. 51:195–208; 1998.

❖ **Paik S, Bryant J, Park C. et al:** ErbB-2 and response to doxorubicin in patients with axillary lymph-node positive, hormone receptor-negative breast cancer. *J Natl Cancer Inst*. 90:1361–70; 1998.

❖ **Pankow JS, Vachon CM, Kuni CC, et al.:** Genetic analysis of mammographic breast density in adult women: evidence of a gene effect. *J Natl Cancer Inst* 89 (8): 549-56; 1997.

❖ **Parajuli P and Singh SM:** Alteration in IL-1 and arginase activity of tumor-associated macrophages: a role in the promotion of tumor growth. *Cancer Lett*. 107: 249-56; 1996.

❖ **Parl FF and Dupont WD:** A retrospective cohort study of histologic risk factors in breast cancer patients. *Cancer*. 50: 2410-6; 1982.

❖ **Patrick L. Fitzgibbons, MD, David L. Page, MD, et al:** Prognostic Factors in Breast Cancer. *Archives of Pathology and Laboratory*

Medicine: Vol. 124, No. 7, pp. 966–78; 2000.

❖ **Peng SH, Deng H, Yang JF, et al:** Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. *World J Gastroenterol.* 11(41):6521-4; 2005.

❖ **Phillips KA:** Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. *J Clin Oncology.* 18 (21 suppl): 107S–112S; 2000.

❖ **Pierre Rudolph, et al:** Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. *Hum Pathol.*32:311-9; 2001.

❖ **Pinder S, Ellis IO, O'Rourke S, et al:** Pathological prognostic factors in breast cancer: vascular invasion: relationship with recurrence and survival in a large series with long term follow up. *Histopathology.* 24:41–7; 1994.

❖ **Pollard JW:** Tumor-educated macrophages promote tumour progression and metastasis. *Nat. Rev. Cancer.* 4: 71–78; 2004.

❖ **Porter D, Lahti-Domenici J, Keshaviah A, et al:** Molecular markers in ductal carcinoma insitu of the breast. *Mol Cancer Res.* 1: 362; 2003.

❖ **Porter PL, Malone KE, Heagerty PJ et al:** Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. *Nat Med.* 3: 222–5; 1997.

❖ **Predine J, Spyrtos F, Prud'homme JR, et al:** Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues: correlation with prognosis and adjuvant hormonal therapy. *Cancer.* 69: 2116–23; 1992.

- ❖ **Presta M:** at presta@med.unibs.it Last updated December 15, 2005.
- ❖ **Prior BM, Yang HT& Terjung RL:** What makes vessels grow with exercise training? *J App Physiol* 97: 1119-28; 2004.
- ❖ **Pu RT, Schott AF, Sturtz DE, Griffith KA, Kleer CG:** Pathologic Features of Breast Cancer Associated With Complete Response to Neoadjuvant Chemotherapy: Importance of Tumor Necrosis. *Am J Surg Pathol.* 29 (3): 354-8; 2005.
- ❖ **Pusztai L, Clover LM, Cooper K, et al:** Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast. *Br J Cancer* 70: 289-92; 1994.

R

- ❖ **Rabinowitz SS and Gordon S:** *J. Cell Sci.* 93, 623±630; 1989.
- ❖ **Rabinowitz SS and Gordon S:** *J. Exp. Med.* 174, 827±836; 1991.
- ❖ **Rahman N, Stratton MR:** The genetics of breast cancer susceptibility. *Ann Rev Genet.* 32: 95–121; 1998.
- ❖ **Ramprasad MP, Terpstra V, Kondratenko N, et al:** Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. *Proc Natl Acad Sci USA.* 93:14833–8; 1996.
- ❖ **Ravandi-Kashani F and Hayes TG:** Male breast cancer: a review of the literature. *Eur J Cancer.* 34(9): 1341-7; 1998.
- ❖ **Reed W, Sandstad B, Holm R, Nesland JM:** The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators. *Int J Surg Pathol.* 11: 485-8; 2003.

- ❖ **Relf M, LeJeune S, Scott PAE, et al:** Expression of the angiogenic growth factors vascular endothelial growth factor, acidic and basic growth factor, tumor growth factor β -1, platelet derived endothelial cell growth factor, placental growth factor, and pleiotropin in human primary breast cancer and its relation to angiogenesis. *Cancer Res.* 57: 963; 1997.
- ❖ **Remvikos Y, Beuzeboc A, Zajdela N, et al:** Correlation of pre-treatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. *J Natl Cancer Inst* 81:1383–7; 1989.
- ❖ **Renz H, Gong JH, Schmidt A, Nain M, Gemsa D:** Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. *J Immunol.* 141: 2388-93; 1988.
- ❖ **Reynolds P, Hurley S, Goldberg DE, Anton-Culver H, et al:** Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. *J Natl Cancer Inst.* 96: 29-37; 2004.
- ❖ **Rilke F, Colnaghi MI, Cascinelli N, et al:** Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. *Int J Cancer.* 49: 44-9; 1991.
- ❖ **Roa BB, Boyd AA, Volcik K, et al:** Ashkenazi Jewish population frequencies for common mutations in *BRCA1* and *BRCA2*. *Nat Genet.* 14:185–7; 1996.
- ❖ **Robaye B, Mosselmans R, Fiers W, Dumont JE, Galand P:** Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. *Am J Pathol.* 138: 447-53; 1991.
- ❖ **Robson M:** Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer. *J Clin Oncol.* 18: 113S-8S; 2000.

-
- ❖ **Rola-Pleszczynski M, Thivierge M, Gagnon N, et al:** Differential regulation of cytokine and cytokine receptor genes by PAF, LTB4 and PGE2. *Journal of Lipid Mediators*. 6, 175-81; 1993.
 - ❖ **Ronckers CM, Erdmann CA, Land CE:** Radiation and breast cancer: a review of current evidence. *Breast Cancer Res*. 7: 21-32; 2005.
 - ❖ **Rosen PP, Beattie EJ, Saigo PE, et al:** Occult axillary lymph node metastases from breast cancers with intramammary lymphatic tumor emboli. *Am J Surg Pathol*. 6:639–41; 1982.
 - ❖ **Rosen PP, Groshen S, Kinne DW, et al:** Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. *J Clin Oncol*. 11:2090-100; 1993.
 - ❖ **Rosen PP and Oberman HA:** Tumors of the mammary gland. In: *Atlas of tumor pathology, Series 3, Fascicle 7*. Washington, DC: Armed Forces Institute of Pathology, 1993.
 - ❖ **Rosen PP:** Rosen's breast pathology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
 - ❖ **Rosen SA:** Endothelial ligands for L-selectin: From lymphocyte recirculation to allograft rejection. *Am J Pathol*. 155: 1013-20; 1999.
 - ❖ **Ross JS, Fletcher JA, Linette GP et al:** The HER-2/*neu* gene and protein in breast cancer 2003: biomarker and target of therapy. *The Oncologist*. 8:307–25; 2003.
 - ❖ **Rossi ML, Jones NR, Candy E, et al:** The mononuclear cell infiltrate compared with survival in high-grade astrocytomas. *Acta Neuropathol* 78: 189-93, 1999.
 - ❖ **Rubio L, Burgos JS, Morera C, et al:** Morphometric study of tumor

angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients. *Pathol Oncol Res*; 6: 210–6; 2000.

❖ **Rundhaug JE:** Matrix metalloproteinases and angiogenesis. *Journal of Cellular and Molecular Medicine* 9(2): 267-85; 2005.

❖ **Russo AA, Jeffrey PD, Patten AK, et al:** Crystal structures of the p27^{Kip1} cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk 2 complex. *Nature*. 382: 325–31; 1996.

❖ **Russo and Russo:** *JNCI Monograph*, vol. 27, pp. 17-37, 2000.

S

❖ **Safe S, Papineni S, Safe S, Papineni S:** The role of xenoestrogenic compounds in the development of breast cancer. *Trends in Pharmacological Sciences*. 27(8):447-54; 2006.

❖ **Salvesen HB and Aksleen LA:** Significance of tumor-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. *Int J Cancer* 84 (5): 539-43, 1999.

❖ **Sarbia M, Bittinger F, Porschen R, et al:** Tumor vascularization and prognosis in squamous cell carcinomas of the esophagus. *Anticancer Res*.16:2117–21; 1996

❖ **Sartor CI:** Epidermal growth factor family receptors and inhibitors: radiation response modulators. *Semin Radiat Oncol*. 13:22–30; 2003

❖ **Satterthwaite AB, Burn TS, Le Beau MM, Tenen DG:** Structure of the human CD34 gene. *Genomics*. 12: 788-94; 1992.

❖ **Scales WE, Chensue SW, Otterness I, Kunkel SL:** Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis

factor but not interleukin-1 alpha or beta-mRNA and cell-associated bioactivity. *J Leukoc Biol.* 45: 416-21; 1989.

❖ **Schatteman GC and Awad O:** In vivo and in vitro properties of CD34+ and CD14+ endothelial cell precursors. *Adv Exp Med Biol.* 522:9-16; 2003.

❖ **Schmidt WA, Boudoussquie AC, Vetto JT, et al:** Lymph node in the human female breast: a review of their detection and significance. *Hum Pathol.* 32: 178-87; 2001.

❖ **Schmitt FC, Soares R, Seruca R:** Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours. *Virchows Arch* 433(6):505-9; 1998.

❖ **Schwartz LH, Koerner FC, Edgerton SM, et al:** pS2 expression and response to hormonal therapy in patients with advanced breast cancer. *Cancer Res.* 51:624–8; 1991.

❖ **Scully R, Chen J, Ochs RL, et al:** Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. *Cell.*90:425–35; 1997.

❖ **SEER 13 Registries:** Public Use Data Set, from data submitted November 2004.

❖ **Shapiro HM:** Practical Flow Cytometry. 3rd ed. New York, NY: Wiley-Liss.:374; 1995.

❖ **Shiloh Y:** ATM and related protein kinases: safeguarding genome integrity. *Nat Rev Cancer.*3:155–68; 2003.

❖ **Shimura S, Yang G, Ebara S, et al:** Reduced infiltration of tumour-associated macrophages in human prostate cancer: association with cancer progression. *Cancer Res* 60: 5857-61, 2000.

- ❖ **Shin SJ and Rosen PP:** Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases. *Am J Surg Pathol* 26(4):413-20; 2002.
- ❖ **Shin SJ, Sheikh FS, Allenby PA, Rosen PP:** Invasive secretory (juvenile) carcinoma arising in ectopic breast tissue of the axilla. *Arch Pathol Lab Med* 125(10):1372-4; 2001.
- ❖ **Shousha S:** Medullary carcinoma of the breast and BRCA1 mutation. *Histopathology* 37: 182-5; 2000.
- ❖ **Simon JF, Korczak CL, Yee, et al:** Racial differences in breast cancer risk to relatives of cases in the women's contraceptive and reproductive experiences (CARE) study. *Meeting: ASCO Annual Meeting; Abstract No: 9514*; 2004.
- ❖ **Singh Y:** Tumor Angiogenesis: Clinical Implications. *Nepal Journal of Neuroscience* 1:61-63, 2004.
- ❖ **Singletary SE, Connolly JL, Singletary SE, Connolly JL:** Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. *CA: a Cancer Journal for Clinicians*. 56(1):37-47; 2006.
- ❖ **Singletary SE, Taylor SH, Guinee VF, et al:** Occurrence and prognosis of contralateral carcinoma of the breast. *J Am Coll Surg* 178 (4): 390-6, 1994.
- ❖ **Skobe M., Hawighorst T., Jackson D.G., et al.:** Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nat Med; Feb 7 (2): 192- 8*, 2001.
- ❖ **Slamon DJ, Clark GM, Wong SG, et al:** Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 235:177–82; 1987.

- ❖ **Smith-Warner SA, Spiegelman D, Yaun SS, et al.:** Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. *JAMA* 285 (6): 769-76; 2001.
- ❖ **Sneige N, Wang J, Baker BA, et al:** Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma insitu of the breast: a report of 24 cases. *Mod Pathol.* 15: 1044-50; 2002.
- ❖ **Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets B, et al:** Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. *Cancer Res.* 56:3216–9; 1996.
- ❖ **Sobol H:** BRCA1-p53 relationship in hereditary breast cancer. *Int J Oncol.* 10:349–53; 1997.
- ❖ **Somers SD, Whisnant CC, Adams DO:** Quantification of the strength of cell-cell adhesion: the capture of tumor cells by activated murine macrophages proceeds through two distinct stages. *J Immunol.* 136: 1490-6; 1986.
- ❖ **Sorlie T, Tibshirani R, Parker J, et al:** Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci USA.* 100:8418–23; 2003.
- ❖ **Soubeyran I, Quenel N, Coindre JM, et al:** pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. *Br J Cancer.* 74:1120–5; 1996.
- ❖ **Spirin KS, Simpson JF, Takeuchi S, et al:** p27/Kip1 mutation found in breast cancer. *Cancer Res.* 56:2400–4; 1996.
- ❖ **St Croix B, Florenes VA, Rak JW, et al:** Impact of the cyclin-dependent kinase inhibitor p27^{Kip1} on resistance of tumor cells to anticancer agents. *Nat Med.* 2:1204–10; 1996.

-
- ❖ **Stabenow E, Tavares MR, Ab'Saber AM, et al:** Angiogenesis as an indicator of metastatic potential in papillary thyroid carcinoma. *Clinics*. 60 (3); 2005.
- ❖ **Stalsberg H and Hartmann WH:** The delimitation of tubular carcinoma of the breast. *Hum Pathol*. 31: 601-7; 2000.
- ❖ **Stamler JS and Feelish M:** Biochemistry of nitric oxide and redox-related species. In *Feelish M, Stamler JS, eds. Methods in Nitric Oxide Research* 19-27. Chichester, 1996.
- ❖ **Steeg PS and Zhou Q:** Cyclins and breast cancer. *Breast Cancer Res Treat*. 52:17–28; 1998.
- ❖ **Steeg PS:** Control of invasion and metastasis. In *Harris JR, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast*. Philadelphia: Lippincott-Raven. pp. 284; 1996.
- ❖ **Steege JCA, Baeten CIM, Thijssen VLJ, et al:** Angiogenic Profile of Breast Carcinoma Determines Leukocyte Infiltration. *Clinical Cancer Research*. 10, 7171–8; 2004.
- ❖ **Strobl H, Scheinecker C, Csmarits B, Majdic O, Knapp W:** Flow cytometric analysis of intracellular CD68 molecule expression in normal and malignant haemopoiesis. *Br J Haematol*. 90:774–82; 1995.
- ❖ **Strom BL, Berlin JA, Weber AL, et al:** Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. *Contraception* 69 (5): 353-60; 2004.
- ❖ **Stuehr DJ and Nathan CF:** Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. *J Exp Med*. 169: 1543-55; 1989.
- ❖ **Suda J, Sudo T, Ito M, et al:** Two types of murine CD34 mRNA

generated by alternative splicing. *Blood*. 79: 2288-42; 1992.

❖ **Surmacz and Eva:** Leptin (Obesity Protein) and Breast Cancer Metastasis. *THOMAS JEFFERSON UNIV PHILADELPHIA PA, MEDICINE: Medicine and Medical Research: pp. 12; 2003.*

❖ **Sutherland DR and Keating A:** The CD34 antigen: structure, biology, and potential clinical applications. *J Hematother*. 1: 115-29; 1992.

❖ **Sutherland DR, et al:** CD34 antigen: Molecular features and potential clinical applications. *Stem Cells*. 11 (suppl 3): S50-7; 1993.

❖ **Swinson D, Jones J, Richardson D, et al:** Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. *Lung Cancer*. 37,235-240; 2002.

T

❖ **Tabar L, Duffy SW, Vitak B, et al:** The natural history of breast carcinoma: what have we learned from screening? *Cancer*. 86(3): 449-62; 1999

❖ **Takanami I, Takeuchi K, Kodaira S:** Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. *Oncology*. 57: 138-42; 1999.

❖ **Takebayashi Y, Natugoe S, Baba M, et al:** Angiogenesis in esophageal squamous cell carcinoma. *Oncol Rep*. 5:401-4; 1998.

❖ **Tan P, Cady B, Wanner M et al:** The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinoma. *Cancer Res*. 57:1259-63; 1997

❖ **Tan PH, Bay BH, Yip G, Selvarajan S, et al:** Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional

regulation of genes related to apoptosis and cell death. *Mod Pathol.* 18(3):374-81; 2005.

❖ **Tandon AK, Clark GM, Chamness GC, et al:** Cathepsin D and prognosis in breast cancer. *N Engl J Med.* 322:297–302; 1990.

❖ **Tanigawa S, Matsumura M, Amaya H, et al:** Tumour vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. *Cancer.* 79:220–5; 1997.

❖ **Tartour E and Fridman WH.** Cytokines and cancer. *International Reviews of Immunology.* 16: 683-704; 1998.

❖ **Tavassoli F and Devilee P:** Pathology and Genetics of Tumours the Breast and Female Genital Organs. "World Health Organization Classification of Tumours". IARC Press, Lyon; 2003.

❖ **Tawfik O, Kimler BF, Davis M, et al:** Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count. *Virchows Arch;* 2007.

❖ **Tenen DG, Satterthwaite AB, Borson R, et al:** Chromosome 1 localization of the gene for CD34, a surface antigen of human stem cells. *Cytogenet Cell Genet.* 53: 55-7; 1990.

❖ **Thor AD, Berry DA, Budman DR, et al:** erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. *J Natl Cancer Inst.* 90:1346–60; 1998.

❖ **Thorlacius S, Sigurdsson S, Bjarnadottir H, et al:** Study of a single BRCA2 mutation with a high carrier frequency in a small population. *Am J Hum Genet.* 60:1079–84; 1997

❖ **Thull D, Vogel V, Thull D, Vogel V:** Recognition and management of hereditary breast cancer syndromes. *Oncologist.* 9(1):13-24; 2004.

-
- ❖ **Tlsty TD and Hein PW:** Know thy neighbor: stromal cells can contribute oncogenic signals. *Curr Opin Genet Dev.* 11: 54; 2001.
- ❖ **Toi M, Tominaga T, Osaki A, Toge T:** Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study. *Breast Cancer Res Treat.* 29:51–58; 1994.
- ❖ **Toomey D, Harmey J, Condron C, et al:** Phenotyping of immune cell infiltrates in breast and colorectal tumours. *Immunol Invest.* 28: 29-41; 1999.
- ❖ **Torisu H, Ono M, Kiryu H, et al:** Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNF α and IL-1 α . *Int J Cancer.* 85: 182–188; 2000.
- ❖ **Torres C, Wang H, Turner J, et al:** Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barret's esophagus-associated adenocarcinoma and squamous cell carcinoma. *Hum Pathol.* 30:753–8; 1999.
- ❖ **Traweek ST, Kandalaft PL, Mehta P, Battifora H:** The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. *Am. J. Clin. Pathol;* 96; 25–31, 1991.
- ❖ **Tsodikov AD, Asselain B and Yakovlev AY:** A distribution of tumor size at detection: an application to breast cancer data. *Biometrics Dec* 53 (4): 1495-502; 1997
- ❖ **Tsutsui S, Kume M and Era S:** Prognostic value of microvessel density in invasive ductal carcinoma of the breast. *Breast Cancer* 10: 312-9, 2003.
- ❖ **Tsutsui S, Yasuda K, Higashi H, et al:** Prognostic implication of p53

protein expression in relation to nuclear pleomorphism and the MIB-1 counts in breast cancer. *Breast Cancer* 11: 160-8; 2004.

❖ **Tsutsui S, Yasuda K, Suzuki K, et al:** Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. *Oncol Rep.* 14(2):425-31; 2005.

❖ **Turner RR, Ollila DW, Stern S, Giuliano AE:** Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. *Am J Surg Pathol.* 23:263–7; 1999.

❖ **Tuxhorn JA, Ayala GE, Rowley DR:** Reactive stroma in prostate cancer progression. *J Urol.* 166:2472–83; 2001.

U

❖ **Umino T, Skold CM, Pirruccello SJ, et al:** Two-colour flow-cytometric analysis of pulmonary alveolar macrophages from smokers. *Eur Respir J.* 13:894–9; 1999.

❖ **Unic I, Stalmeier PF, Peer PG, et al:** A review on family history of breast cancer: screening and counseling proposals for women with familial (non-hereditary) breast cancer. *Patient Educ Couns* 32 (1-2): 117-27; 1997.

❖ **Uzzan B, Nicolas P, Cucherat M and Perret GY:** Microvessel Density as a Prognostic Factor in Women with Breast Cancer. *Cancer Research.* 64, 2941-55; 2004.

V

❖ **Vacca A, Ribatti D, Ruco L, et al:** Angiogenesis extent and

macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. *Br J Cancer*. 79: 965–70; 1999.

❖ **Vachon CM, King RA, Atwood LD, et al:** Preliminary sibpair linkage analysis of percent mammographic density. *J Natl Cancer Inst* 91 (20): 1778-9; 1999.

❖ **Vahteristo P, Bartkova J, Eerola H et al:** A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. *Am J Hum Genet*.71:432–8; 2002.

❖ **Valkovic T, Dobrila F, Melato M, Sasso F, et al:** Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophage in invasive ductal breast carcinoma. *Virchows Arch*. 440 (6): 583-8; 2002.

❖ **van de Rijn M and Gilks C.B.:** Applications of microarrays to histopathology. *Histopathology*; 44, 97–108, 2004.

❖ **van de Rijn M, Lombard CM, Rouse RV:** Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum and lung. *Am. J. Surg. Pathol.*; 18; 814–20, 1994.

❖ **van de Vijver MJ, Peterse JL, Mooi WJ et al:** Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. *N Engl J Med*. 319:1239–45; 1988.

❖ **van-Ravenswaay-Claasen HH, Kluin PM, Fleuren GJ:** Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. *Lab Invest*. 67: 166-74; 1992.

❖ **Van't Veer LJ, Dai H, van de Vijver MJ, et al:** Gene expression profiling predict clinical outcome of breast cancer. *Nature*. 415: 530;

2002.

- ❖ **Varley JM, Swallow JE, Brammer WJ et al:** Alterations to either c-*erbB2* (neu) or c-*myc* proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. *Oncogene*. 1:423–30; 1987.
- ❖ **Velicer CM, Heckbert SR, Lampe JW, et al:** Antibiotic use in relation to the risk of breast cancer. *JAMA*. Feb 18; 291(7):827-35; 2004.
- ❖ **Vermeulen K, Van Bockstaele DR, Berneman ZN:** The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. *Cell Prolif*. 36:131–49; 2003.
- ❖ **Vermeulen PB, Libura M, Libura J, et al:** Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. *Breast Cancer Res Treat*. 42:165–72; 1997.
- ❖ **Veronesi U, De Palo G, Marubini E, et al.:** Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. *J Natl Cancer Inst* 91 (21): 1847-56; 1999.
- ❖ **Veronesi U, Paganelli G, Galimberti V, et al:** Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. *Lancet*. 349:1864–7; 1997.
- ❖ **Visscher DW, Sarker F, Tabaczka P, Crissman J:** Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma. *Mod Pathol*. 9:642–6; 1996.
- ❖ **Vogel VG:** Atypia in the assessment of breast cancer risk: mplications for management. *Diagn Cytopathol*. 30:151-7; 2004.
- ❖ **Volante M, Sapino A, Croce S, et al:** Heterogenous versus homogeneous genetic nature of multiple loci of insitu carcinoma of the breast. *Hum Pathol*. 34: 1163-9; 2003.

❖ **Volodko N, Reiner A, Rudas M, Jakesz R:** Tumour-associated macrophages in breast cancer and their prognostic correlations. *Breast*. 7: 99-105; 1998.

❖ **Volpi A, Bacci F, Paradiso A, Saragoni L, et al:** Prognostic relevance of histological grade and its components in node-negative breast cancer patients. *Mod Pathol*. 17(9):1038-44; 2004.

W

❖ **Waldman FM, DeVries S, Chew KL, et al:** Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. *J Natl Cancer Inst*. 92:313–20; 2000.

❖ **Waldman FM, Hwang ES, Etzell J, et al:** Genomic alterations in tubular breast carcinomas. *Hum Pathol*. 32: 222-6; 2001.

❖ **Walter:** Lymphatic permeation in cancer breast. *Am J Pathol*. 135: 781-92; 1987.

❖ **Wang J, Costantino JP, Tan-Chiu E, et al:** Lower-category benign breast disease and the risk of invasive breast cancer. *J Natl Cancer Inst*. 96:616-20; 2004.

❖ **Wang W, Goswami S, Sahai E, et al:** Tumor cells caught in the act of invading: their strategy for enhanced cell motility. *Trends Cell Biol*. 15: 138–45; 2005.

❖ **Wang X, Mori I, Tang W, Yang Q, et al:** Metaplastic Carcinoma of the Breast: p53 Analysis Identified the Same Point Mutation in the Three Histologic Components. *Mod Pathol* 14:1183-6; 2001.

❖ **Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M:** Pathologic analysis of sentinel and non-sentinel lymph nodes in breast

carcinoma: a multi-center study. *Cancer*; 88:1099–107; 2000.

- ❖ **Weber BL and Garber J:** Diseases of the breast, Familial Breast Ca. Philadelphia. 2: 168-84; 1996.
- ❖ **Weidner N, Semple JP, Welch WR, Folkman J:** Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. *N Engl J Med*. 324:1–8; 1991.
- ❖ **Weiss JR, Moysich KB, Swede H, et al:** Epidemiology of male breast cancer. *Cancer Epidemiology, Biomarkers & Prevention*. 14(1):20-6; 2005.
- ❖ **Weiss MC, Fowble BL, Solin LJ, et al:** Outcome of conservative therapy for invasive breast cancer by histologic subtype. *Int J Radiat Oncol Biol Phys*. 23: 941; 1992.
- ❖ **Wells WA, Carney PA, Ellassen MS, et al:** Pathologists agreement with experts and reproducibility of breast ductal carcinoma-in-situ classification scheme. *Am J Surg Pathol*. 24: 651-9; 2000.
- ❖ **Wenger CR and Clark GM:** S-phase fraction and breast cancer: a decade of experience [review]. *Breast Cancer Res Treat*. 51: 255–65; 1998.
- ❖ **Wernicke M, Pineiro LC, Caramutti D, et al:** Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan. *Mod Pathol*. 16 (2):99-107; 2003.
- ❖ **Wheeler DT, Tai LH, and Tavassoli FA:** Tubulolobular carcinoma of the breast: a histologic and immunohistochemical analysis. *Mod Pathol*. 16: 50a-51a; 2003.
- ❖ **Williams WL Jr, Powers M, Wagman LD:** Cancer of the male breast: a review. *J Natl Med Assoc* 88(7): 439-43; 1996.

- ❖ **Winchester DJ:** Male breast cancer. *Semin Surg Oncol.* 12(5): 364-9; 1996.
- ❖ **Wiseman BS and Werb Z:** Stromal effect on mammary gland development and breast cancer. *Science.* 296: 1046; 2002.
- ❖ **Witton CJ, Reeves JR, Going JJ et al:** Expression of the HER 1-4 family of receptor tyrosine kinases in breast cancer. *J Pathol.* 200:290–7; 2003.
- ❖ **Wood WC, Muss HB, Solin LJ, Olopade OI:** Malignant Tumors of the Breast. In DeVita VT, Hellman S, Rosenberg SA eds. *Cancer: Principles & Practice of Oncology.* 7th Edition. Philadelphia: Lippincott Williams & Wilkins; 2005.
- ❖ **Wooster R and Weber BL:** Breast and Ovarian Cancer. *Genomic Medicine.* Volume 348:2339-47; 2003.
- ❖ **Wooster R, Bignell G, Lancaster J et al:** Identification of the breast cancer susceptibility gene *BRCA2*. *Nature.* 378:789–92; 1995.
- ❖ **Wooster R, Neuhausen SL, Mangion J et al:** Localization of a breast cancer susceptibility gene, *BRCA2*, to chromosome 13q12-13. *Science.* 265:2088–90; 1994.
- ❖ **World Cancer Research Fund., American Institute for Cancer Research.:** Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington, DC: The Institute; 1997.
- ❖ **Writing Group for the Women's Health Initiative Investigators:** Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 288 (3): 321-33; 2002.
- ❖ **Wyckoff J, Wang W, Lin EY, et al:** A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary

tumors. *Cancer Res.* 64: 7022–9; 2004.

X

❖ **Xiong M, Elson G, Legarda D and Leibovich SJ:** Production of vascular endothelial growth factor by murine macrophages. *Am J Pathol* 153: 587-98, 1998.

Y

❖ **Yamaguchi H, Pixley F and Condeelis J:** Invadopodia and podosomes in tumor invasion. *Eur. J. Cell Biol.* 85 (3-4): 213-8; 2006.

❖ **Yarden Y and Sliwkowski MX:** Untangling the Erb-B signaling network. *Nat Rev Mol Cell Biol.* 2:127–37; 2001.

Z

❖ **Zhang S, Hunter DJ, Forman MR, et al.:** Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. *J Natl Cancer Inst* 91 (6): 547-56; 1999.

❖ **Zhou S, Wang G-P, Liu C and Zhou M:** Eukaryotic Initiation Factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. *BMC Cancer.* 6:231; 2006.

❖ **Ziegler J:** An unlikely link? Researches probe viral role in breast cancer [news]. *Natl Cancer Inst.* 89: 608; 1997.

❖ **Zou Z, Gao C, Nagaich AK et al:** p53 regulates the expression of the tumor suppressor gene maspin. *J Biol Chem.* 275:6051–4; 2000.